Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (300255.SZ)
CNY 19.98
(-2.06%)
CNY 19.98
(-2.06%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.79 Billion CNY | -6.2% |
| 2022 | 2.98 Billion CNY | 40.8% |
| 2021 | 2.11 Billion CNY | 23.17% |
| 2020 | 1.71 Billion CNY | 40.89% |
| 2019 | 1.22 Billion CNY | -7.68% |
| 2018 | 1.32 Billion CNY | 20.75% |
| 2017 | 1.09 Billion CNY | 29.92% |
| 2016 | 842.59 Million CNY | 11.3% |
| 2015 | 757.07 Million CNY | 22.53% |
| 2014 | 617.86 Million CNY | 71.74% |
| 2013 | 359.77 Million CNY | 22.89% |
| 2012 | 292.77 Million CNY | 47.29% |
| 2011 | 198.77 Million CNY | -5.91% |
| 2010 | 211.25 Million CNY | 97.15% |
| 2009 | 107.15 Million CNY | 3.87% |
| 2008 | 103.16 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 2.93 Billion CNY | 4.85% |
| 2024 Q2 | 2.97 Billion CNY | 1.48% |
| 2024 Q3 | 2.91 Billion CNY | -2.06% |
| 2023 Q4 | 2.79 Billion CNY | 0.76% |
| 2023 Q3 | 2.77 Billion CNY | -7.66% |
| 2023 FY | 2.79 Billion CNY | -6.2% |
| 2023 Q2 | 3 Billion CNY | 2.43% |
| 2023 Q1 | 2.93 Billion CNY | -1.58% |
| 2022 Q3 | 2.65 Billion CNY | -2.0% |
| 2022 Q2 | 2.71 Billion CNY | 8.66% |
| 2022 FY | 2.98 Billion CNY | 40.8% |
| 2022 Q1 | 2.49 Billion CNY | 17.95% |
| 2022 Q4 | 2.98 Billion CNY | 12.11% |
| 2021 Q1 | 1.68 Billion CNY | -1.98% |
| 2021 FY | 2.11 Billion CNY | 23.17% |
| 2021 Q2 | 1.57 Billion CNY | -6.28% |
| 2021 Q4 | 2.11 Billion CNY | 2.26% |
| 2021 Q3 | 2.07 Billion CNY | 31.11% |
| 2020 FY | 1.71 Billion CNY | 40.89% |
| 2020 Q1 | 1.3 Billion CNY | 6.7% |
| 2020 Q2 | 1.53 Billion CNY | 17.62% |
| 2020 Q3 | 1.8 Billion CNY | 17.73% |
| 2020 Q4 | 1.71 Billion CNY | -4.64% |
| 2019 Q1 | 1.29 Billion CNY | -1.66% |
| 2019 FY | 1.22 Billion CNY | -7.68% |
| 2019 Q2 | 1.22 Billion CNY | -5.66% |
| 2019 Q3 | 1.34 Billion CNY | 9.75% |
| 2019 Q4 | 1.22 Billion CNY | -9.33% |
| 2018 Q2 | 1.39 Billion CNY | 19.05% |
| 2018 FY | 1.32 Billion CNY | 20.75% |
| 2018 Q4 | 1.32 Billion CNY | 11.0% |
| 2018 Q3 | 1.19 Billion CNY | -14.58% |
| 2018 Q1 | 1.17 Billion CNY | 6.96% |
| 2017 Q4 | 1.09 Billion CNY | 13.07% |
| 2017 FY | 1.09 Billion CNY | 29.92% |
| 2017 Q3 | 968.13 Million CNY | 20.85% |
| 2017 Q2 | 801.1 Million CNY | -8.0% |
| 2017 Q1 | 870.81 Million CNY | 3.35% |
| 2016 Q4 | 842.59 Million CNY | 7.51% |
| 2016 Q2 | 861.11 Million CNY | 15.85% |
| 2016 Q1 | 743.27 Million CNY | -1.82% |
| 2016 FY | 842.59 Million CNY | 11.3% |
| 2016 Q3 | 783.7 Million CNY | -8.99% |
| 2015 Q3 | 681.83 Million CNY | -3.26% |
| 2015 Q2 | 704.78 Million CNY | 17.12% |
| 2015 Q1 | 601.78 Million CNY | -2.6% |
| 2015 FY | 757.07 Million CNY | 22.53% |
| 2015 Q4 | 757.07 Million CNY | 11.04% |
| 2014 Q4 | 617.86 Million CNY | 2.83% |
| 2014 FY | 617.86 Million CNY | 71.74% |
| 2014 Q2 | 622.78 Million CNY | 46.33% |
| 2014 Q1 | 425.6 Million CNY | 18.3% |
| 2014 Q3 | 600.83 Million CNY | -3.52% |
| 2013 Q2 | 380.35 Million CNY | 11.66% |
| 2013 Q4 | 359.77 Million CNY | 4.24% |
| 2013 Q3 | 345.14 Million CNY | -9.26% |
| 2013 FY | 359.77 Million CNY | 22.89% |
| 2013 Q1 | 340.63 Million CNY | 16.35% |
| 2012 Q1 | 188.78 Million CNY | -5.02% |
| 2012 FY | 292.77 Million CNY | 47.29% |
| 2012 Q2 | 211.47 Million CNY | 12.02% |
| 2012 Q3 | 296.81 Million CNY | 40.36% |
| 2012 Q4 | 292.77 Million CNY | -1.36% |
| 2011 Q3 | 230.5 Million CNY | -26.35% |
| 2011 Q2 | 312.98 Million CNY | 0.0% |
| 2011 Q4 | 198.77 Million CNY | -13.77% |
| 2011 FY | 198.77 Million CNY | -5.91% |
| 2010 FY | 211.25 Million CNY | 97.15% |
| 2010 Q4 | 211.25 Million CNY | 0.0% |
| 2009 FY | 107.15 Million CNY | 3.87% |
| 2008 FY | 103.16 Million CNY | 0.0% |